A hereditary ovarian cancer family with rare pathogenic splicing mutation: Implications for variant interpretation

Cancer Genet. 2021 Aug:256-257:127-130. doi: 10.1016/j.cancergen.2021.05.007. Epub 2021 May 26.

Abstract

The BRCA1/2 gene is important for assessing the risk of familial/hereditary ovarian cancer (OC). This case is a patient with OC, and two of her immediate family members are cancer patients. We sequenced the coding and splicing regions of 42 OC susceptibility genes, and found a rare pathogenic splicing mutation BRCA1:c.132C > T (p.cys44 =) in 2 patients. Although the mutation is synonymous, software prediction and functional verification have shown that it affects alternative splicing and leads to frameshift mutations (c.131_134del). Chromosome microarray analysis of the tissue samples revealed the presence of a BRCA1 gene deletion with a fragment size of 1.42 Mb and an HRD score of 71. In addition, the proband showed a sensitive response to platinum treatment. This case suggests the clinical significance of OC susceptibility genes sequencing and HRD scoring in screening hereditary OC families.

Keywords: Familial/hereditary ovarian cancer syndrome; Genatic detection; Homologous recombination deficiency.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Base Sequence
  • Family
  • Female
  • Genetic Predisposition to Disease*
  • Humans
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Ovarian Neoplasms / genetics*
  • Pedigree
  • RNA Splicing / genetics*